RevenanasBook a free audit

Layoffs

Agios axes 100-plus R&D roles while awaiting FDA decision

November 6, 2026

Biotech

Layoffs

Key Facts

Signal Type

Layoffs

Industry

Biotech

Companies

Agios Pharmaceuticals, Truist Securities, Leerink Partners, Novo Nordisk

Date

November 6, 2026

What Happened

Agios Pharmaceuticals announced a restructuring that eliminates over 100 R&D positions, representing more than 35% of its R&D team. The company expects to incur approximately $11 million in restructuring charges in 2026, with cost savings realized in 2027. CEO Brian Goff stated the move 'right sizes' the operating model to maximize the mitapivat franchise.

Who Is Affected

The layoffs primarily impact R&D staff at the Massachusetts-based biopharma, which employed 539 full-time workers as of December 2025. Agios is focusing on commercialization and late-stage development of two rare hematology candidates, while deprioritizing early-stage assets like AG-181.

Market Impact

Analysts view the restructuring favorably. Truist Securities noted 'cost discipline provides another lever toward profitability.' Leerink Partners said the R&D headcount reduction reflects 'sharper allocation of capital toward commercialization.' Agios now estimates profitability (excluding irregular costs) by 2028. The company had $907 million in cash as of September 30. The FDA delay on mitapivat for sickle cell disease pushed the decision to February 2027, causing a stock decline.

  • Truist Securities: 'cost discipline provides another lever toward profitability'
  • Leerink Partners: 'sharper allocation of capital toward commercialization'
  • Agios estimates profitability by 2028
  • $907 million cash on hand as of Sept 30
  • FDA decision on mitapivat delayed to Feb 2027

What to Watch

The FDA's decision on mitapivat for sickle cell disease, now expected by February 1, 2027, will be a key catalyst. Agios is also open to unlocking value from non-core assets, which could lead to partnerships or divestitures. The company's ability to execute its commercial strategy and achieve profitability in 2028 will be closely monitored.

Related coverage

Source:

BioSpace

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner